Patent application number | Description | Published |
20090208421 | Process for preparing a pharmaceutical formulation of contrast agents - The invention relates to a process for preparing a liquid pharmaceutical formulation containing a complex of macrocyclic chelate with a lanthanide and a mol/mol amount of free macrocyclic chelate of between 0.002% and 0.4%, advantageously between 0.02% and 0.3% and very advantageously between 0.025% and 0.25%, the macrocyclic chelate advantageously being chosen from DOTA, NOTA, DOTAGA, DO3A, BT-DO3A, HP-DO3A and PCTA, and is preferably DOTA, the said process comprising the following successive steps:
| 08-20-2009 |
20090299172 | Water Diffusion imaging and Uspio - The invention relates to a method of water diffusion imaging in magnetic resonance imaging in an area of diagnostic interest, characterized in that it comprises, in combination, the administration of a contrast product capable of generating a signal specifically in its specific location area, said location area being included in said area of interest, the application of a water diffusion imaging sequence to the whole area of interest, and the reading of the images in the area of interest, the specific signal due to the contrast product significantly and specifically modifying the signal in the specific location area relative to the signal of the whole area of interest. | 12-03-2009 |
20100111876 | USE OF METAL NANOPARTICLES IN THE DIAGNOSIS OF ALZHEIMER'S DISEASE - The invention relates to the use of metal nanoparticles for the preparation of a composition for diagnosing Alzheimer's disease by MRI. | 05-06-2010 |
20100297025 | Novel compositions magnetic particles covered with gem-bisphosphonate derivatives - The invention relates to a composition comprising acid magnetic particles (p) based on an iron compound, the acid magnetic particles (p) being complexed by one or more gem-bisphosphonate compounds, of formula I: | 11-25-2010 |
20110092806 | Compounds Comprising a Biological Target Recognizing Part, Coupled to a Signal Part Capable of Complexing Gallium - The invention concerns compounds comprising a biological target recognizing part, coupled to a signal part capable of complexing gallium. The invention also concerns methods for obtaining said compounds, screening methods capable of selecting such compounds for chemical synthesis thereof and their diagnostic applications, in particular in PET, PET/IRM, PET CT imaging. | 04-21-2011 |
20110129425 | PROCESS FOR PREPARING A PHARMACEUTICAL FORMULATION OF CONTRAST AGENTS - The invention relates to a process for preparing a liquid pharmaceutical formulation containing a complex of macrocyclic chelate with a lanthanide and a mol/mol amount of free macrocyclic chelate of between 0.002% and 0.4%, advantageously between 0.02% and 0.3% and very advantageously between 0.025% and 0.25%, the macrocyclic chelate advantageously being chosen from DOTA, NOTA, DOTAGA, DO3A, BT-DO3A, HP-DO3A and PCTA, and is preferably DOTA, the said process comprising the following successive steps: b) preparation of a liquid pharmaceutical composition containing, firstly, the complex of macrocyclic chelate with a lanthanide, and, secondly, free macrocyclic chelate and/or free lanthanide; c) measurement in the pharmaceutical formulation obtained in step b) of the concentration of free macrocyclic chelate C ch1 and/or of free lanthanide C lan1; d) adjustment of C ch1 and/or of C lan1 so as to obtain C ch1=C tch1 and C lan1=0, wherein C t ch1 is the target concentration of free macrocyclic chelate in the final liquid pharmaceutical formulation. | 06-02-2011 |
20120064003 | COMPLEX FOLATE-NOTA-Ga68 - The present invention concerns a Ga68 complex of formula FOLATE-(LINKER)i-NOTA-Ga | 03-15-2012 |
20130336898 | PROCESS FOR PREPARING A PHARMACEUTICAL FORMULATION OF CONTRAST AGENTS - The invention relates to a process for preparing a liquid pharmaceutical formulation containing a complex of macrocyclic chelate with a lanthanide and a mol/mol amount offree macrocyclic chelate of between 0.002% and 0.4%, advantageously between 0.02% and 0.3% and very advantageously between 0.025% and 0.25%, the macrocyclic chelate advantageously being chosen from DOTA, NOTA, DOTAGA, DO3A, BT-DO3A, HP-DO3A and PCTA, and is preferably DOTA, the said process comprising the following successive steps: b) preparation of a liquid pharmaceutical composition containing, firstly, the complex of macrocyclic chelate with a lanthanide, and, secondly, free macrocyclic chelate and/or free lanthanide; c) measurement in the pharmaceutical formulation obtained in step b) of the concentration of free macrocyclic chelate C | 12-19-2013 |